Tezacitabine blocks tumor cells in G1 and S phases of the cell cycle and induces apoptotic cell death.

Abstract

Tezacitabine (FMdC) is a new cytostatic/cytotoxic agent widely investigated in clinical trials and on the cellular level. In a previous paper (3) we worked on human and murine leukemia (L-1210, HL-60, and MOLT-4) cells, and in this paper we investigated the influence of FMdC on the cell cycle and apoptosis in vitro of three other leukemias (CCRF-SB, KG-1, and Jurkat), and human solid tumor (carcinoma) cell lines (COLO-205, MCF-7, and PC-3). We found that FMdC induces the G1 (at concentrations higher than 10 nM). and S-phase (at low concentration) leaky block of the cell cycle. FMdC also effectively induces apoptotic death of cells by the caspase 3/7 pathway. We found also that FMdC induces intensive changes in the protein metabolism. These changes are correlated with the cell death.

• Authors: Janusz S Skierski, Mirosława Koronkiewicz, Paweł Grieb
• Journal: Acta poloniae pharmaceutica (Acta Pol Pharm) 2005 May-Jun Vol. 62 Issue 3 Pg. 195-205 ISSN: 0001-6837 [Print] Poland
• PMID: 16193812 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• Deoxycytidine
• tezacitabine

Topics

• Animals
• Antineoplastic Agents (pharmacology)
• Apoptosis (drug effects)
• Cell Line, Tumor
• Deoxycytidine (analogs & derivatives, pharmacology)
• G1 Phase (drug effects)
• Humans
• Jurkat Cells
• Mice
• S Phase (drug effects)